For ICD definition

For ICD. For Collaborator (if separate from above): Division Director, Division of Technology (same as above) Development and Transfer NIH Office of Technology Transfer ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇ Tel: ▇▇▇-▇▇▇-▇▇▇▇ Fax: ▇▇▇-▇▇▇-▇▇▇▇ For ICD: For Collaborator (if separate from above): ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇, M.D., Ph.D. (same as above) Surgery Branch, NCI ▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇. ▇▇, CRC Room 3-3940 ▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇ Tel. ▇▇▇-▇▇▇-▇▇▇▇ Fax: ▇▇▇-▇▇▇-▇▇▇▇ PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH TITLE OF CRADA: Cooperative Research and Development Agreement for the Development of NCI Proprietary Peripheral Blood Autologous T Cell Therapies Using Genetically Modified Peripheral. Blood Lymphocytes That Express NCI Proprietary T Cell Receptors and/or Chimeric Antigen Receptors for Use in the Immunotherapy for Patients with Metastatic Cancer, Utilizing the Expertise of Kite Pharma in Development and Manufacturing of Cancer Immunotherapies PHS [ICD] Component: National Cancer Institute (NCI) ICD CRADA Principal Investigator: ▇▇▇▇▇▇ ▇ ▇▇▇▇▇▇▇▇▇, M.D., PhD. Collaborator: Kite Pharma, Inc. Collaborator CRADA Principal Investigator: ▇▇▇ ▇▇▇▇▇▇▇▇▇▇, Ph.D. Term of CRADA: Five (5) years from the Effective Date […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 23 of 52 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH GOALS OF THIS CRADA […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 24 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH INTRODUCTION […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 25 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 26 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH

AI-Powered Contracts

Draft, Review & Redline at the Speed of AI

For ICD. For Collaborator (if separate from above): Division Director, Division of Technology Same as above Development and Transfer NIH Office of Technology Transfer ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇ Tel: ▇▇▇-▇▇▇-▇▇▇▇ Fax: ▇▇▇-▇▇▇-▇▇▇▇

For ICD. For Collaborator (if separate from above): Division Director, Division of Technology Development and Transfer NIH Office of Technology Transfer ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇ Rockville, Maryland ▇▇▇▇▇-▇▇▇▇ Tel: ▇▇▇-▇▇▇-▇▇▇▇ Fax: ▇▇▇-▇▇▇-▇▇▇▇ For ICD: For Collaborator: Name: Branch: Address: Telephone: TITLE OF CRADA: PHS [ICD] Component: ICD CRADA Principal Investigator: Collaborator: Collaborator CRADA Principal Investigator: Term of CRADA: ( ) years from the Effective Date

Examples of For ICD in a sentence

PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH For ICD: For Collaborator: Technology Transfer Center Chief Medical Officer National Cancer Institute Attn: ▇▇.
No.02661 MODEL ADOPTED June 18, 2009 For ICD: For Collaborator: Director ▇▇▇▇▇ ▇▇▇▇▇ Technology Transfer Center Tracon Pharmaceuticals, Inc.
No. MODEL ADOPTED 2005 For ICD: For Collaborator: Technology Transfer Center [***] National Cancer Institute President and CEO ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇., ▇▇▇▇▇ ▇▇▇ BN ImmunoTherapeutics, Inc.
FOR ICD: [***] 9/9/11 [***] Date Deputy Director, NCI FOR COLLABORATOR: [***] 10/3/11 [***] Date President and Chief Executive Officer For ICD: For Collaborator: Technology Transfer Center [***] National Cancer institute President and CEO ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇., ▇▇▇▇▇ ▇▇▇ BN ImmunoTherapeutics, Inc.
No.02663 MODEL ADOPTED June 18, 2009 For ICD: Technology Transfer Center ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇., ▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ Tel.
No. MODEL ADOPTED June 18, 2009 Page 21 of 52 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH For ICD: For Collaborator: Technology Transfer Center ▇▇▇ ▇▇▇▇▇▇▇▇▇▇, Ph.D. ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇., ▇▇▇▇▇ ▇▇▇ President & Chief Executive Officer Rockville, MD 20852 Kite Pharma, Inc.
No. ______ MODEL ADOPTED June 18, 2009 For ICD: For Collaborator: Technology Transfer Center, NCI Genesis Biopharma, Inc.
No. 02734 MODEL ADOPTED June 18, 2009 For ICD: For Collaborator: Technology Transfer Center, NCI Genesis Biopharma, Inc.
No. _______ MODEL ADOPTED June 18, 2009 Page 21 of 55 CONTACTS INFORMATION PAGE For ICD: Technology Transfer Center ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇., ▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ Tel.
For ICD: For Collaborator: For ICD: For Collaborator (if separate from above): Division Director, Division of Technology Development and TransferNIH Office of Technology Transfer6011 ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇▇▇▇: 301-496-7057Fax: ▇▇▇-▇▇▇-▇▇▇▇ For ICD: For Collaborator: Name: Branch: Address: Telephone: PHS ECT-CRADA Case Ref.

More Definitions of For ICD

For ICD. For Collaborator (if separate from above): Division Director, Division of Technology Development and Transfer NIH Office of Technology Transfer 60▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇ ▇el: ▇▇▇-▇▇▇-▇▇▇▇ Fax: ▇▇▇-▇▇▇-▇▇▇▇ For ICD: For Collaborator: Branch: Address: Telephone: TITLE OF CRADA: ICD CRADA Principal Investigator: Collaborator: Collaborator CRADA Principal Investigator: Term of CRADA: ( ) years from the Effective Date

For ICD. For Collaborator: Technology Transfer Center Chief Medical Officer National Cancer Institute Attn: ▇▇. ▇▇▇▇▇ ▇▇▇▇▇▇▇ Rockville, MD 20852 1450 Infinite Dr. Phone: ▇▇▇-▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ Fax: ▇▇▇-▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ Fax: ▇▇▇-▇▇▇-▇▇▇▇ Patenting and Licensing

For ICD. For Collaborator (if separate from above): Division Director, Division of Technology Development and Transfer Chief Medical Officer NIH Office of Technology Transfer Attn: ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇ 1450 Infinite Dr. Rockville, Maryland 20852-3804 ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ Tel: ▇▇▇-▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ Fax: ▇▇▇-▇▇▇-▇▇▇▇ Fax: ▇▇▇-▇▇▇-▇▇▇▇ Delivery of Materials Identified In Appendix B (if any)

For ICD. For Collaborator: ▇▇. ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ N.A. ▇▇▇▇ ▇▇ ▇▇▇▇ ▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ TITLE OF CRADA: Identification of agents regulating Nuclear Receptor Corepressor (N-CoR) pathway for glioma tumor cell differentiation PHS[ICD] Component: National Institute of Neurological Disorders and Stroke ICD Principal Investigator: ▇▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ICD Co-Principal Investigator: ▇▇. ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ Collaborator: Lixte, Inc. Collaborator Principal Investigator: ▇▇. ▇▇▇▇ ▇.Kovach TERM OF CRADA: 2 (Two) years from the Effective Date The National Institute of Neurological Disorders and Stroke (“NINDS”) in Bethesda, Maryland, and Lixte, Inc. will collaborate in the identification and evaluation of agents that target the Nuclear Receptor CoRepressor (N-CoR) pathway for glioma tumor cell differentiation. NINDS and Lixte, Inc. will also conduct research to determine if expression of N-CoR correlates with prognosis in glioma patients. The subject of this CRADA is limited to identifying agents that act synergistically with retinoic acid (RA) or okadaic acid to inhibit proliferation of Glioblastoma multiforme (GBM) cells and to determine if expression of Nuclear Receptor Corepressor (N-CoR) correlates with prognosis in glioma patients.

For ICD. For Collaborator: